Binding affinity for estrogen receptor, by competition with [3H]estradiol
|
None
|
990.0
nM
|
|
Inhibition of epidermal growth factor (EGF) receptor from A431 cell membranes at 150 uM
|
Homo sapiens
|
63.0
%
|
|
Transcriptional potency (EC50) at Human estrogen receptor Beta
|
None
|
6.0
nM
|
|
Ability to activate estrogen receptor 1-mediated transcription.
|
None
|
950.0
nM
|
|
Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha.
|
None
|
48.0
nM
|
|
Binding affinity against human estrogen receptor alpha in competitive binding assay
|
None
|
92.0
nM
|
|
Binding affinity towards human estrogen receptor alpha(ERalpha)
|
None
|
395.0
nM
|
|
Inhibition of binding of 17 beta-estradiol to human Estrogen receptor alpha
|
None
|
370.0
nM
|
|
Ability to activate estrogen receptor 2-mediated transcription.
|
None
|
200.0
nM
|
|
Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta.
|
None
|
4.1
nM
|
|
Agonist activity in transcriptional activation assay in SH-SY5Y neuroblastoma cells expressing Estrogen receptor beta
|
Homo sapiens
|
1.7
nM
|
|
Inhibition of [3H]17-beta-estradiol binding to human recombinant Estrogen receptor beta.
|
None
|
200.0
nM
|
|
Binding affinity against human estrogen receptor beta (ER beta) in competitive binding assay
|
None
|
4.0
nM
|
|
Binding affinity towards estrogen receptor beta by [3H]17-beta-estradiol displacement.
|
None
|
390.0
nM
|
|
Binding affinity towards human estrogen receptor beta (ERbeta)
|
None
|
10.0
nM
|
|
Inhibition of binding of 17 beta-estradiol to human Estrogen receptor beta
|
None
|
83.0
nM
|
|
Inhibition of binding of 17 beta-estradiol to human Estrogen receptor beta
|
None
|
24.0
nM
|
|
Inhibition of 5-HIAA formation in isolated Hamster Liver Mitochondria at 0.3 uM.
|
Cricetulus griseus
|
31.3
%
|
|
Inhibition of 5-HIAA formation in isolated Hamster Liver Mitochondria at 0.9 uM.
|
Cricetulus griseus
|
65.0
%
|
|
Inhibition of 5-HIAA formation in isolated Hamster Liver Mitochondria at 3 uM.
|
Cricetulus griseus
|
77.6
%
|
|
Inhibition of 5-HIAA formation in isolated Hamster Liver Mitochondria at 9 uM.
|
Cricetulus griseus
|
96.8
%
|
|
Inhibition of Hamster Liver mitochondrial Monoamine oxidase.
|
Cricetulus griseus
|
900.0
nM
|
|
Transcriptional potency (EC50) at Human estrogen receptor alpha
|
None
|
20.0
nM
|
|
Binding affinity for human Estrogen receptor beta
|
Homo sapiens
|
98.7
nM
|
|
Binding affinity for human Estrogen receptor beta
|
Homo sapiens
|
98.7
nM
|
|
Binding affinity for human Estrogen receptor beta
|
Homo sapiens
|
10.0
nM
|
|
Binding affinity for human Estrogen receptor alpha
|
Homo sapiens
|
395.0
nM
|
|
Inhibition of [3H]17-beta-estradiol binding to human estrogen receptor beta expressed in Escherichia coli
|
Homo sapiens
|
9.7
nM
|
|
Inhibition of [3H]17-beta-estradiol binding to human estrogen receptor alpha expressed in Escherichia coli
|
Homo sapiens
|
395.0
nM
|
|
Inhibitory concentration against human ER beta expressed in Escherichia coli was determined using [3H]17-beta-estradiol as radio ligand
|
Homo sapiens
|
10.0
nM
|
|
Inhibitory concentration against human ER alpha expressed in Escherichia coli was determined using [3H]17-beta-estradiol as radio ligand
|
Homo sapiens
|
395.0
nM
|
|
Binding affinity for human Estrogen receptor beta
|
Homo sapiens
|
10.0
nM
|
|
Binding affinity for human Estrogen receptor alpha
|
Homo sapiens
|
395.0
nM
|
|
Displacement of [3H]17beta-estradiol from recombinant human ERalpha expressed in 293T cells
|
Homo sapiens
|
29.4
nM
|
|
Displacement of [3H]17beta-estradiol from recombinant human ERbeta expressed in 293T cells
|
Homo sapiens
|
1.3
nM
|
|
Displacement of [3H]estrone from ER beta
|
Homo sapiens
|
61.0
nM
|
|
Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay
|
Homo sapiens
|
73.0
nM
|
|
Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay at 10 uM
|
Homo sapiens
|
956.0
nM
|
|
Displacement of [3H]E2 from human recombinant ERbeta LBD by SPA
|
Homo sapiens
|
25.0
nM
|
|
Inhibition of human LBD of of ERalpha
|
Homo sapiens
|
9.7
nM
|
|
Inhibition of human LBD of ERbeta
|
Homo sapiens
|
395.0
nM
|
|
Inhibition of human ERbeta by radioligand binding assay
|
Homo sapiens
|
9.7
nM
|
|
Inhibition of human ERalpha by radioligand binding assay
|
Homo sapiens
|
395.0
nM
|
|
Displacement of [3H]17beta-estradiol from recombinant human ERalpha
|
Homo sapiens
|
580.0
nM
|
|
Displacement of [3H]17beta-estradiol from recombinant human ERbeta
|
Homo sapiens
|
6.8
nM
|
|
Agonist activity at human ERalpha expressed in yeast AH109 by yeast two hybrid assay
|
Homo sapiens
|
810.0
nM
|
|
Agonist activity at human ERbeta expressed in yeast AH109 by yeast two hybrid assay
|
Homo sapiens
|
28.0
nM
|
|
Inhibition of invasion of human HT1080 cells at 3 uM after 24 hrs
|
Homo sapiens
|
5.5
%
|
|
Inhibition of invasion of human HT1080 cells at 10 uM after 24 hrs
|
Homo sapiens
|
35.1
%
|
|
Inhibition of invasion of human HT1080 cells at 30 uM after 24 hrs
|
Homo sapiens
|
43.2
%
|
|
Antiproliferative activity against human HT1080 cells at 3 uM after 24 hrs by MTT assay
|
Homo sapiens
|
-6.2
%
|
|
Antiproliferative activity against human HT1080 cells at 10 uM after 24 hrs by MTT assay
|
Homo sapiens
|
-1.2
%
|
|
Antiproliferative activity against human HT1080 cells at 30 uM after 24 hrs by MTT assay
|
Homo sapiens
|
12.5
%
|
|
Antiproliferative activity against human HT1080 cells at 3 uM after 48 hrs by MTT assay
|
Homo sapiens
|
3.8
%
|
|
Antiproliferative activity against human HT1080 cells at 10 uM after 48 hrs by MTT assay
|
Homo sapiens
|
9.3
%
|
|
Antiproliferative activity against human HT1080 cells at 30 uM after 48 hrs by MTT assay
|
Homo sapiens
|
25.3
%
|
|
Antiproliferative activity against human HT1080 cells at 3 uM after 72 hrs by MTT assay
|
Homo sapiens
|
-0.9
%
|
|
Antiproliferative activity against human HT1080 cells at 10 uM after 72 hrs by MTT assay
|
Homo sapiens
|
1.7
%
|
|
Antiproliferative activity against human HT1080 cells at 30 uM after 72 hrs by MTT assay
|
Homo sapiens
|
22.5
%
|
|
Antiproliferative activity against human HT1080 cells at 3 uM after 24 hrs by calcein-AM assay
|
Homo sapiens
|
2.8
%
|
|
Antiproliferative activity against human HT1080 cells at 10 uM after 24 hrs by calcein-AM assay
|
Homo sapiens
|
6.1
%
|
|
Antiproliferative activity against human HT1080 cells at 30 uM after 24 hrs by calcein-AM assay
|
Homo sapiens
|
17.3
%
|
|
Antiproliferative activity against human HT1080 cells at 3 uM after 48 hrs by calcein-AM assay
|
Homo sapiens
|
2.0
%
|
|
Antiproliferative activity against human HT1080 cells at 10 uM after 48 hrs by calcein-AM assay
|
Homo sapiens
|
5.1
%
|
|
Antiproliferative activity against human HT1080 cells at 30 uM after 48 hrs by calcein-AM assay
|
Homo sapiens
|
17.6
%
|
|
Antiproliferative activity against human HT1080 cells at 3 uM after 72 hrs by calcein-AM assay
|
Homo sapiens
|
1.5
%
|
|
Antiproliferative activity against human HT1080 cells at 10 uM after 72 hrs by calcein-AM assay
|
Homo sapiens
|
6.0
%
|
|
Antiproliferative activity against human HT1080 cells at 30 uM after 72 hrs by calcein-AM assay
|
Homo sapiens
|
17.2
%
|
|
Inhibition of human ERalpha
|
Homo sapiens
|
10.0
nM
|
|
Inhibition of human ERbeta
|
Homo sapiens
|
395.0
nM
|
|
Growth inhibition of human KG1a cells at 5 uM after 48 hrs
|
Homo sapiens
|
10.0
%
|
|
Inhibition of human DNA topoisomerase 2 catalytic domain-mediated knotted bacteriophage P4Virl dell0 DNA unknotting by agarose gel electrophoresis
|
Homo sapiens
|
30.0
ug.mL-1
|
|
Inhibition of EGFR
|
None
|
0.2
ug.mL-1
|
|
Inhibition of beef heart mitochondrial NADH oxidase assessed per mg of protein
|
Bos taurus
|
365.0
nM
|
|
Inhibition of cow milk xanthine oxidase at 50 ug/mL
|
Bos taurus
|
0.0
%
|
|
Displacement of [3H]estradiol from human recombinant ERalpha
|
Homo sapiens
|
300.0
nM
|
|
Inhibition of Saccharomyces cerevisiae fatty acid synthase
|
Saccharomyces cerevisiae
|
50.0
ug.mL-1
|
|
Antifungal activity against Candida albicans ATCC 90028
|
Candida albicans
|
50.0
ug.mL-1
|
|
Antifungal activity against Cryptococcus neoformans ATCC 90113
|
Cryptococcus neoformans
|
50.0
ug.mL-1
|
|
Inhibition of EGFR in human A431 cells
|
Homo sapiens
|
0.1
ug.mL-1
|
|
Inhibition of EGFR in human A431 cells
|
Homo sapiens
|
0.7
ug.mL-1
|
|
Inhibition of EGFR
|
None
|
0.7
ug.mL-1
|
|
Antifungal activity against MDR knockout Candida albicans DSY1024 after 24 hrs by XTT assay
|
Candida albicans
|
100.0
ug.mL-1
|
|
Antifungal activity against wild type Candida albicans SC5314 after 24 hrs by XTT assay
|
Candida albicans SC5314
|
100.0
ug.mL-1
|
|
Displacement of [3H]estradiol from human recombinant ERbeta
|
Homo sapiens
|
18.0
nM
|
|
Estrogenic activity in human Ishikawa cells assessed as induction of alkaline phosphatase activity after 4 days by para-nitrophenol release assay
|
Homo sapiens
|
510.0
nM
|
|
Antiinflammatory activity against FMLP/CB stimulated human neutrophils assessed as inhibition of elastase release at 10 ug/mL relative to control
|
Homo sapiens
|
51.6
%
|
|
Antiinflammatory activity against FMLP/CB stimulated human neutrophils assessed as inhibition of superoxide anion generation at 10 ug/mL relative to control
|
Homo sapiens
|
65.0
%
|
|
Antifungal activity against Giardia intestinalis ATCC 30888 after 48 hrs by XTT assay
|
Giardia intestinalis
|
5.0
ug.mL-1
|
|
Inhibition of EGFR
|
None
|
0.2
ug.mL-1
|
|
Inhibition of human salivary alpha-amylase
|
Homo sapiens
|
25.1
%
|
|
Inhibition of reduced carboxymethylated kappa-casein fibril formation at 50 ug/mL measured every 5 mins after 1000 mins by thioflavin T staining-based binding assay
|
None
|
95.0
%
|
|
Inhibition of beta amyloid (1 to 42) fibril formation at 50 ug/mL by thioflavin T staining-based binding assay
|
None
|
43.0
%
|
|
Inhibition of EGFR at 100 uM by ELISA
|
None
|
80.0
%
|
|
Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs
|
Homo sapiens
|
0.0
%
|
|
Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs
|
Homo sapiens
|
0.0
%
|
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/cytochalasin B-induced elastase release at 10 ug/ml after 5 mins
|
Homo sapiens
|
52.0
%
|
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/cytochalasin B-induced superoxide anion generation at 10 ug/ml after 5 mins by spectrophotometry
|
Homo sapiens
|
65.0
%
|
|
Inhibition of Influenza A PR/8/34 H1N1 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay
|
Influenza A virus (A/Puerto Rico/8/1934(H1N1))
|
20.84
ug.mL-1
|
|
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release at 10 ug/mL
|
Homo sapiens
|
51.6
%
|
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2
|
Plasmodium falciparum Dd2
|
4.1
ug.mL-1
|
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum PoW
|
Plasmodium falciparum
|
2.0
ug.mL-1
|
|
Inhibition of human aldehyde oxidase
|
Homo sapiens
|
340.0
nM
|
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins
|
Homo sapiens
|
0.54
ug.mL-1
|
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins
|
Homo sapiens
|
6.99
ug.mL-1
|
|
Negative chronotropic activity against potassium-induced contraction in guinea pig right atrium assessed as decrease atrial rate at 10'-4 M relative to control
|
Cavia porcellus
|
68.0
%
|
|
Negative ionotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease atrial rate at 5 X 10'-6 M relative to control
|
Cavia porcellus
|
71.0
%
|
|
Negative ionotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease atrial rate
|
Cavia porcellus
|
28.0
nM
|
|
Vasorelaxant activity in potassium depolarized guinea pig aortic strip assessed as inhibition of calcium-induced contraction at 5 X 10'-5 M
|
Cavia porcellus
|
22.0
%
|
|
Negative ionotropic activity in potassium depolarized guinea pig longitudinal smooth muscle assessed as inhibition of calcium-induced contraction at 5 X 10'-5 M
|
Cavia porcellus
|
84.0
%
|
|
Bronchodilatory activity in guinea pig trachea assessed as inhibition of carbachol-induced contraction at 10'-5 M
|
Cavia porcellus
|
14.0
%
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol)
|
None
|
135.0
nM
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol)
|
None
|
39.0
nM
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol)
|
None
|
2.88
nM
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol)
|
None
|
0.594
nM
|
|
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method
|
Electrophorus electricus
|
7.3
%
|
|
Inhibition of horse BChE at 2 mg/ml by Ellman's method
|
Equus caballus
|
10.47
%
|
|
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting
|
Homo sapiens
|
84.9
%
|
|
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
-5.0
%
|
|
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
67.9
%
|
|
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced superoxide anion production treated 5 mins before FMLP addition measured after 10 mins
|
Homo sapiens
|
690.0
nM
|
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
95.56
%
|
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
39.06
%
|
|
Inhibition of rat serum BuChE using butyrylthiocholine iodide as substrate at 50 uM after 15 mins by Ellman's method
|
Rattus norvegicus
|
5.0
%
|
|
Inhibition of human erythrocytes AchE using acetylthiocholine iodide as substrate at 50 uM after 15 mins by Ellman's method
|
Homo sapiens
|
5.0
%
|
|
Inhibition of electric eel AchE using acetylthiocholine iodide as substrate at 50 uM after 15 mins by Ellman's method
|
Electrophorus electricus
|
5.0
%
|
|
Inhibition of rat cortex homogenate AchE using acetylthiocholine iodide as substrate at 50 uM after 15 mins by Ellman's method
|
Rattus norvegicus
|
5.0
%
|
|
Agonist activity at human ER-beta transfected in HEK293 cells after 48 hrs by luciferase reporter gene assay
|
Homo sapiens
|
19.95
nM
|
|
Agonist activity at human ER-alpha transfected in HEK293 cells after 48 hrs by luciferase reporter gene assay
|
Homo sapiens
|
501.19
nM
|
|
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis
|
Human immunodeficiency virus 1
|
13.9
ug.mL-1
|
|
Inhibition of porcine pancreatic lipase at 100 ug/ml pre-incubated for 15 mins before p-nitrophenylbutyrate substrate addition by microplate reader based method
|
Sus scrofa
|
3.2
%
|
|
Binding Assay: The binding affinity and selectivity of candidate molecules yielded from database screening were determined by a fluorescent polarization competitive binding assay using purified baculovirus-expressed human ER beta or ER alpha and a fluorescent estrogen ligand EL Red (PanVera Corp.).
|
Homo sapiens
|
98.7
nM
|
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM after 24 hrs by Griess reagent based assay relative to control
|
Mus musculus
|
13.0
%
|
|
Inhibition of LPS-induced NF-kappaB transcription (unknown origin) expressed in human SW480 cells at 10 uM by luciferase reporter gene assay
|
Homo sapiens
|
14.0
%
|
|
Inhibition of recombinant human PTP1B using p-nitrophenyl phosphate as substrate at 10 uM after 30 mins relative to control
|
Homo sapiens
|
29.0
%
|
|
Inhibition of mushroom tyrosinase at 10 uM using L-tyrosine as substrate incubated for 15 mins followed by substrate addition relative to control
|
Agaricus bisporus
|
2.0
%
|
|
Inhibition of DPP4 (unknown origin) using Gly-Pro-AMC as substrate preincubated for 4 secs followed by substrate addition and measured after 30 mins by luminescence assay
|
Homo sapiens
|
480.0
nM
|
|
Estrogenic activity at ERalpha in human Ishikawa cells assessed as induction of alkaline phosphatase activity using p-nitrophenol as substrate treated for 96 hrs followed by substrate addition by spectrophotometric method
|
Homo sapiens
|
240.0
nM
|
|
Estrogenic activity at ERbeta (unknown origin) expressed in human MDA-MB-231/beta41 cells after 18 hrs by renilla luciferase reporter gene assay
|
Homo sapiens
|
2.4
nM
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
22.48
%
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
5.66
%
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
6.45
%
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
-7.01
%
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Staphylococcus aureus subsp. aureus
|
3.06
%
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Acinetobacter baumannii
|
1.42
%
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Escherichia coli
|
2.99
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
-27.03
%
|
|
Inhibition of yeast alpha-glucosidase at 50 uM using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by microplate reader analysis
|
Saccharomyces cerevisiae
|
70.0
%
|
|
Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins relative to control
|
Escherichia coli
|
40.0
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
22.58
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
1.568
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.35
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.02
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.35
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.02
%
|
|
Inhibition of recombinant human PTP1B (1 to 321 residues) expressed in Escherichia coli at 10 uM using p-nitrophenyl phosphate as substrate incubated for 30 mins relative to control
|
Homo sapiens
|
60.0
%
|
|
Inhibition of alpha-Glucosidase (unknown origin) at 10 uM using pNPG as substrate incubated for 30 mins relative to control
|
Homo sapiens
|
58.4
%
|
|
Inhibition of electric eel AChE at 100 uM using acetylthiocholine iodide as substrate by Ellman's colorimetric analysis relative to control
|
Electrophorus electricus
|
12.0
%
|
|
Inhibition of equine serum BuChE at 100 uM using butyrylthiocholine iodide as substrate by Ellman's colorimetric analysis relative to control
|
Equus caballus
|
41.0
%
|
|
Competitive inhibition of almond beta-glucosidase at 100 uM using p-nitrophenyl glycosides as substrate measured for 125 secs by spectrophotometry analysis relative to control
|
Prunus dulcis
|
44.0
%
|
|
Uncompetitive inhibition of Saccharomyces cerevisiae alpha-glucosidase at 100 uM using p-nitrophenyl glycosides as substrate measured for 125 secs by spectrophotometry analysis relative to control
|
Saccharomyces cerevisiae
|
84.0
%
|
|
Cytotoxicity against mouse B16-BL6 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
Mus msuculus
|
4.18
ug.mL-1
|
|
Inhibition of recombinant human MEK4 (14 to 377 residues) after 5 mins by Western blot analysis
|
Homo sapiens
|
400.0
nM
|
|
Inhibition of electric eel AChE at 25 uM by Ellman's method relative to control
|
Electrophorus electricus
|
5.0
%
|
|
Inhibition of equine serum BChE at 25 uM by Ellman's method relative to control
|
Equus caballus
|
5.0
%
|
|
Inhibition of AChE in human erythrocytes at 25 uM by Ellman's method relative to control
|
Homo sapiens
|
5.0
%
|
|
Inhibition of human serum BChE at 25 uM by Ellman's method relative to control
|
Homo sapiens
|
5.0
%
|
|
Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL complex formation at 10 uM incubated for 15 mins in presence of cardiolipin by Trp-59 fluorescence assay relative to control
|
Homo sapiens
|
50.0
%
|
|
Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL peroxidase activity at 10 uM up to 20 mins in presence of cardiolipin by Amplex red staining based fluorescence assay relative to control
|
Homo sapiens
|
51.0
%
|
|
Inhibition of cytochrome c (unknown origin) assessed as reduction reduction of cyt c from its ferric state to ferrous state at 10 uM incubated for 20 mins in presence of cardiolipin by UV-vis Spectrophotometric assay relative to control
|
Homo sapiens
|
0.0
%
|
|